{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:27:34Z","timestamp":1792315654703,"version":"4.4.0"},"reference-count":48,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>OCD is characterized by obsessions and compulsions that cause distress, are time-consuming, and interfere with a patient's social, occupational, or other areas of functioning. SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD. Several potential strategies have been evaluated for enhancing patient response, including high-dose SSRI therapy, antipsychotic augmentation, and memantine augmentation. Three patient cases are used to explore treatment guidelines, evaluate existing literature, and provide pharmacotherapy recommendations for the management of patients with OCD when first-line therapy fails.<\/jats:p>","DOI":"10.9740\/mhc.2022.10.300","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T13:27:51Z","timestamp":1667482071000},"page":"300-308","source":"Crossref","is-referenced-by-count":5,"title":["Moving beyond first-line treatment options for OCD"],"prefix":"10.9740","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0076-2238","authenticated-orcid":true,"given":"Chris","family":"Paxos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2022110313260911000_i2168-9709-12-5-300-b01","unstructured":"National Institute of Mental Health [Internet].\n          Obsessive-compulsive disorder.\n          Bethesda\n          (MD): National Institute of Mental Health; c2022 [cited 2022 May 1]. Available from: www.nimh.nih.gov\/health\/statistics\/obsessive-compulsive-disorder-ocd"},{"key":"2022110313260911000_i2168-9709-12-5-300-b02","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association.\n          Diagnostic and statistical manual of mental disorders. 5th ed.\n\t\t\t\t\tArlington (VA):\n\t\t\t\t\tAmerican Psychiatric Association;2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2022110313260911000_i2168-9709-12-5-300-b03","unstructured":"Sadock\n              BJ,\n            \n            \n              Sadock\n              VA,\n            \n            \n              Ruiz\n              P.\n            \n          \n          Kaplan & Sadock's synopsis of psychiatry. 11th ed.\n\t\t\t\t\tNew York:\n\t\t\t\t\tWolters Kluwer;2015."},{"key":"2022110313260911000_i2168-9709-12-5-300-b04","unstructured":"National Institute of Mental Health [Internet].\n          Statistics.\n          Bethesda\n          (MD): National Institute of Mental Health; c2022 [cited 2022 May 1]. Available from: www.nimh.nih.gov\/health\/statistics"},{"key":"2022110313260911000_i2168-9709-12-5-300-b05","doi-asserted-by":"crossref","unstructured":"Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder.\n\t\t\t\t\tJ Am Acad Child Adolesc Psychiatry.\n\t\t\t\t\t2012;\n\t\t\t\t\t51(1):\n\t\t\t\t\t98-\n\t\t\t\t\t113.\n\t\t\t\t\tDOI: 10.1016\/j.jaac.2011.09.019. PubMed PMID: 22176943.","DOI":"10.1016\/j.jaac.2011.09.019"},{"key":"2022110313260911000_i2168-9709-12-5-300-b06","doi-asserted-by":"crossref","unstructured":"Kayser\n              RR.\n            \n          \n          Pharmacotherapy for treatment-resistant obsessive-compulsive disorder.\n          J Clin Psychiatry.\n          2020;\n\t\t\t\t\t81(5):19ac13182.DOI: 10.4088\/JCP.19ac13182. PubMed PMID: 32926602.","DOI":"10.4088\/JCP.19ac13182"},{"key":"2022110313260911000_i2168-9709-12-5-300-b07","doi-asserted-by":"crossref","unstructured":"Sinopoli\n              VM,\n            \n            \n              Burton\n              CL,\n            \n            \n              Kronenberg\n              S,\n            \n            \n              Arnold\n              PD.\n            \n          \n          A review of the role of serotonin system genes in obsessive-compulsive disorder.\n\t\t\t\t\tNeurosci Biobehav Rev.\n\t\t\t\t\t2017;\n\t\t\t\t\t80:\n\t\t\t\t\t372-\n\t\t\t\t\t81.\n\t\t\t\t\tDOI: 10.1016\/j.neubiorev.2017.05.029. PubMed PMID: 28576508.","DOI":"10.1016\/j.neubiorev.2017.05.029"},{"key":"2022110313260911000_i2168-9709-12-5-300-b08","doi-asserted-by":"crossref","unstructured":"Baldwin\n              DS,\n            \n            \n              Anderson\n              IM,\n            \n            \n              Nutt\n              DJ,\n            \n            \n              Allgulander\n              C,\n            \n            \n              Bandelow\n              B,\n            \n            \n              den Boer\n              JA,\n            \n            et al.\n          \n          Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2014;\n\t\t\t\t\t28(5):\n\t\t\t\t\t403-\n\t\t\t\t\t39.\n\t\t\t\t\tDOI: 10.1177\/0269881114525674. PubMed PMID: 24713617.","DOI":"10.1177\/0269881114525674"},{"key":"2022110313260911000_i2168-9709-12-5-300-b09","doi-asserted-by":"crossref","unstructured":"Katzman\n              MA,\n            \n            \n              Bleau\n              P,\n            \n            \n              Blier\n              P,\n            \n            \n              Chokka\n              P,\n            \n            \n              Kjernisted\n              K,\n            \n            \n              van Ameringen\n              M,\n            \n            et al.\n          \n          Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.\n\t\t\t\t\tBMC Psychiatry.\n\t\t\t\t\t2014;\n\t\t\t\t\t14Suppl 1:\n\t\t\t\t\tS1.\n\t\t\t\t\tDOI: 10.1186\/1471-244X-14-S1-S1. PubMed PMID: 25081580; PubMed Central PMCID: PMC4120194.","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"2022110313260911000_i2168-9709-12-5-300-b10","doi-asserted-by":"crossref","unstructured":"Farris\n              SG,\n            \n            \n              McLean\n              CP,\n            \n            \n              Van Meter\n              PE,\n            \n            \n              Simpson\n              HB,\n            \n            \n              Foa\n              EB.\n            \n          \n          Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t2013;\n\t\t\t\t\t74(7):\n\t\t\t\t\t685-\n\t\t\t\t\t90.\n\t\t\t\t\tDOI: 10.4088\/JCP.12m07789. PubMed PMID: 23945445.","DOI":"10.4088\/JCP.12m07789"},{"key":"2022110313260911000_i2168-9709-12-5-300-b11","unstructured":"Substance Abuse and Mental Health Services Administration [Internet].\n          Creating a healthier life: a step-by-step guide to wellness.\n          Rockville\n          (MD): Substance Abuse and Mental Health Services Administration; c2016 [cited 2022 Jul 12]. Available from: https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/sma16-4958.pdf"},{"key":"2022110313260911000_i2168-9709-12-5-300-b12","unstructured":"American Psychiatric Association [Internet].\n          Practice guideline for the treatment of patients with obsessive-compulsive disorder.\n          Washington: American Psychiatric Association; c2007 [cited 2022 May 1]. Available from: https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/ocd.pdf"},{"key":"2022110313260911000_i2168-9709-12-5-300-b13","doi-asserted-by":"crossref","unstructured":"Bandelow\n              B,\n            \n            \n              Zohar\n              J,\n            \n            \n              Hollander\n              E,\n            \n            \n              Kasper\n              S,\n            \n            \n              M\u00f6ller\n              H-J,\n            \n            \n              Zohar\n              J,\n            \n            et al.\n          \n          World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.\n\t\t\t\t\tWorld J Biol Psychiatry.\n\t\t\t\t\t2008;\n\t\t\t\t\t9(4):\n\t\t\t\t\t248-\n\t\t\t\t\t312.\n\t\t\t\t\tDOI: 10.1080\/15622970802465807. PubMed PMID: 18949648.","DOI":"10.1080\/15622970802465807"},{"key":"2022110313260911000_i2168-9709-12-5-300-b14","doi-asserted-by":"crossref","unstructured":"Goodman\n              W,\n            \n            \n              Price\n              LH,\n            \n            \n              Rasmussen\n              SA,\n            \n            \n              Mazure\n              C,\n            \n            \n              Fleischmann\n              RL,\n            \n            \n              Hill\n              CL,\n            \n            et al.\n          \n          The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.\n          Arch Gen Psychiatry.\n          1989;\n\t\t\t\t\t46(11):\n\t\t\t\t\t1006-\n\t\t\t\t\t11.\n\t\t\t\t\tPubMed PMID: 2684084.","DOI":"10.1001\/archpsyc.1989.01810110048007"},{"key":"2022110313260911000_i2168-9709-12-5-300-b15","doi-asserted-by":"crossref","unstructured":"Goodman\n              W,\n            \n            \n              Price\n              LH,\n            \n            \n              Rasmussen\n              SA,\n            \n            \n              Mazure\n              C,\n            \n            \n              Delgado\n              P,\n            \n            \n              Heninger\n              GR,\n            \n            et al.\n          \n          The Yale-Brown Obsessive Compulsive Scale. II.\n\t\t\t\t\tValidity. Arch Gen Psychiatry.\n\t\t\t\t\t1989;\n\t\t\t\t\t46(11):\n\t\t\t\t\t1012-\n\t\t\t\t\t6.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.1989.01810110054008. PubMed PMID: 2510699.","DOI":"10.1001\/archpsyc.1989.01810110054008"},{"key":"2022110313260911000_i2168-9709-12-5-300-b16","unstructured":"Sajatovic\n              M,\n            \n            \n              Ramirez\n              LF.\n            \n          \n          Rating scales in mental health. 2nd ed.\n\t\t\t\t\tHudson (OH):\n\t\t\t\t\tLexi-Comp, Inc;2003."},{"key":"2022110313260911000_i2168-9709-12-5-300-b17","unstructured":"Koran\n              LM,\n            \n            \n              Simpson\n              HB\n            \n          \n          [Internet]. Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder.\n          Washington: American Psychiatric Association; c2013 [cited 2022 May 1]. Available from: https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/ocd-watch.pdf"},{"key":"2022110313260911000_i2168-9709-12-5-300-b18","doi-asserted-by":"crossref","unstructured":"Del Casale\n              A,\n            \n            \n              Sorice\n              S,\n            \n            \n              Padovano\n              A,\n            \n            \n              Simmaco\n              M,\n            \n            \n              Ferracuti\n              S,\n            \n            \n              Lamis\n              DA,\n            \n            et al.\n          \n          Psychopharmacological treatment of obsessive-compulsive disorder (OCD).\n\t\t\t\t\tCurr Neuropharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t17(8):\n\t\t\t\t\t710-\n\t\t\t\t\t36.\n\t\t\t\t\tDOI: 10.2174\/1570159X16666180813155017. PubMed PMID: 30101713.","DOI":"10.2174\/1570159X16666180813155017"},{"key":"2022110313260911000_i2168-9709-12-5-300-b19","doi-asserted-by":"crossref","unstructured":"Bloch\n              MH,\n            \n            \n              McGuire\n              J,\n            \n            \n              Landeros-Weisenberger\n              A,\n            \n            \n              Leckman\n              JF,\n            \n            \n              Pittenger\n              C.\n            \n          \n          Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder.\n\t\t\t\t\tMol Psychiatry.\n\t\t\t\t\t2010;\n\t\t\t\t\t15(8):\n\t\t\t\t\t850-\n\t\t\t\t\t5.\n\t\t\t\t\tDOI: 10.1038\/mp.2009.50. PubMed PMID: 19468281; PubMed Central PMCID: PMC2888928.","DOI":"10.1038\/mp.2009.50"},{"key":"2022110313260911000_i2168-9709-12-5-300-b20","doi-asserted-by":"crossref","unstructured":"Ninan\n              PT,\n            \n            \n              Koran\n              LM,\n            \n            \n              Kiev\n              A,\n            \n            \n              Davidson\n              JRT,\n            \n            \n              Rasmussen\n              SA,\n            \n            \n              Zajecka\n              JM,\n            \n            et al.\n          \n          High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t2006;\n\t\t\t\t\t67(1):\n\t\t\t\t\t15-\n\t\t\t\t\t22.\n\t\t\t\t\tDOI: 10.4088\/jcp.v67n0103. PubMed PMID: 16426083.","DOI":"10.4088\/JCP.v67n0103"},{"key":"2022110313260911000_i2168-9709-12-5-300-b21","doi-asserted-by":"crossref","unstructured":"Dougherty\n              DD,\n            \n            \n              Jameson\n              M,\n            \n            \n              Deckersbach\n              T,\n            \n            \n              Loh\n              R,\n            \n            \n              Thompson-Hollands\n              J,\n            \n            \n              Jenike\n              M,\n            \n            et al.\n          \n          Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.\n\t\t\t\t\tInt Clin Psychopharmacol.\n\t\t\t\t\t2009;\n\t\t\t\t\t24(6):\n\t\t\t\t\t306-\n\t\t\t\t\t11.\n\t\t\t\t\tDOI: 10.1097\/YIC.0b013e32833119d8. PubMed PMID: 19730388.","DOI":"10.1097\/YIC.0b013e32833119d8"},{"key":"2022110313260911000_i2168-9709-12-5-300-b22","doi-asserted-by":"crossref","unstructured":"Rabinowitz\n              I,\n            \n            \n              Baruch\n              Y,\n            \n            \n              Barak\n              Y.\n            \n          \n          High-dose escitalopram for the treatment of obsessive-compulsive disorder.\n\t\t\t\t\tInt Clin Psychopharmacol.\n\t\t\t\t\t2008;\n\t\t\t\t\t23(1):\n\t\t\t\t\t49-\n\t\t\t\t\t53.\n\t\t\t\t\tDOI: 10.1097\/YIC.0b013e3282f0f0c5. PubMed PMID: 18090508.","DOI":"10.1097\/YIC.0b013e3282f0f0c5"},{"key":"2022110313260911000_i2168-9709-12-5-300-b23","doi-asserted-by":"crossref","unstructured":"Stein\n              DJ,\n            \n            \n              Carey\n              PD,\n            \n            \n              Lochner\n              C,\n            \n            \n              Seedat\n              S,\n            \n            \n              Fineberg\n              N,\n            \n            \n              Andersen\n              EW.\n            \n          \n          Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.\n\t\t\t\t\tCNS Spectr.\n\t\t\t\t\t2008;\n\t\t\t\t\t13(6):\n\t\t\t\t\t492-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1017\/s1092852900016722. PubMed PMID: 18567973.","DOI":"10.1017\/S1092852900016722"},{"key":"2022110313260911000_i2168-9709-12-5-300-b24","doi-asserted-by":"crossref","unstructured":"Stein\n              DJ,\n            \n            \n              Andersen\n              EW,\n            \n            \n              Overo\n              KF.\n            \n          \n          Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.\n\t\t\t\t\tBraz J Psychiatry.\n\t\t\t\t\t2007;\n\t\t\t\t\t29(4):\n\t\t\t\t\t303-\n\t\t\t\t\t7.\n\t\t\t\t\tDOI: 10.1590\/s1516-44462007000400003. PubMed PMID: 18200396.","DOI":"10.1590\/S1516-44462007000400003"},{"key":"2022110313260911000_i2168-9709-12-5-300-b25","doi-asserted-by":"crossref","unstructured":"Landeros-Weisenberger\n              A,\n            \n            \n              Bloch\n              MH,\n            \n            \n              Kelmendi\n              B,\n            \n            \n              Wegner\n              R,\n            \n            \n              Nudel\n              J,\n            \n            \n              Dombrowski\n              P,\n            \n            et al.\n          \n          Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.\n\t\t\t\t\tJ Affect Disord.\n\t\t\t\t\t2010;\n\t\t\t\t\t121(1-2):\n\t\t\t\t\t175-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1016\/j.jad.2009.06.010. PubMed PMID: 19577308.","DOI":"10.1016\/j.jad.2009.06.010"},{"key":"2022110313260911000_i2168-9709-12-5-300-b26","doi-asserted-by":"crossref","unstructured":"Ghaleiha\n              A,\n            \n            \n              Shahidi\n              KM,\n            \n            \n              Afzali\n              S,\n            \n            \n              Matinnia\n              N.\n            \n          \n          Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized controlled trial.\n\t\t\t\t\tInt J Psychiatry Clin Pract.\n\t\t\t\t\t2013;\n\t\t\t\t\t17(1):\n\t\t\t\t\t44-\n\t\t\t\t\t7.\n\t\t\t\t\tDOI: 10.3109\/13651501.2012.687449. PubMed PMID: 22731399.","DOI":"10.3109\/13651501.2012.687449"},{"key":"2022110313260911000_i2168-9709-12-5-300-b27","unstructured":"Foong\n              A-L,\n            \n            \n              Grindrod\n              KA,\n            \n            \n              Patel\n              T,\n            \n            \n              Kellar\n              J.\n            \n          \n          Demystifying serotonin syndrome (or serotonin toxicity).\n\t\t\t\t\tCan Fam Physician.\n\t\t\t\t\t2018;\n\t\t\t\t\t64(10):\n\t\t\t\t\t720-\n\t\t\t\t\t7.\n\t\t\t\t\tPubMed PMID: 30315014."},{"key":"2022110313260911000_i2168-9709-12-5-300-b28","unstructured":"National Institutes of Health [Internet].\n          News. National Library of Medicine. Bethesda\n          (MD): National Institutes of Health; c2022 [cited 2022 May 1]. Available at: https:\/\/dailymed.nlm.nih.gov\/dailymed"},{"key":"2022110313260911000_i2168-9709-12-5-300-b29","doi-asserted-by":"crossref","unstructured":"Fineberg\n              NA,\n            \n            \n              Reghunandanan\n              S,\n            \n            \n              Simpson\n              HB,\n            \n            \n              Phillips\n              KA,\n            \n            \n              Richter\n              MA,\n            \n            \n              Matthews\n              K,\n            \n            et al.\n          \n          Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults.\n\t\t\t\t\tPsychiatry Res.\n\t\t\t\t\t2015;\n\t\t\t\t\t227(1):\n\t\t\t\t\t114-\n\t\t\t\t\t25.\n\t\t\t\t\tDOI: 10.1016\/j.psychres.2014.12.003. PubMed PMID: 25681005.","DOI":"10.1016\/j.psychres.2014.12.003"},{"key":"2022110313260911000_i2168-9709-12-5-300-b30","doi-asserted-by":"crossref","unstructured":"Leung\n              JG,\n            \n            \n              Palmer\n              BA.\n            \n          \n          Psychosis or obsessions? Clozapine associated with worsening obsessive-compulsive symptoms.\n\t\t\t\t\tCase Rep Psychiatry.\n\t\t\t\t\t2016;\n\t\t\t\t\t2016:\n\t\t\t\t\t2180748.\n\t\t\t\t\tDOI: 10.1155\/2016\/2180748. PubMed PMID: 27313938; PubMed Central PMCID: PMC4904080.","DOI":"10.1155\/2016\/2180748"},{"key":"2022110313260911000_i2168-9709-12-5-300-b31","doi-asserted-by":"crossref","unstructured":"Fonseka\n              TM,\n            \n            \n              Richter\n              MA,\n            \n            \n              M\u00fcller\n              DJ.\n            \n          \n          Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.\n\t\t\t\t\tCurr Psychiatry Rep.\n\t\t\t\t\t2014;\n\t\t\t\t\t16(11):\n\t\t\t\t\t510.\n\t\t\t\t\tDOI: 10.1007\/s11920-014-0510-8. PubMed PMID: 25256097.","DOI":"10.1007\/s11920-014-0510-8"},{"key":"2022110313260911000_i2168-9709-12-5-300-b32","doi-asserted-by":"crossref","unstructured":"Dold\n              M,\n            \n            \n              Aigner\n              M,\n            \n            \n              Lanzenberger\n              R,\n            \n            \n              Kasper\n              S.\n            \n          \n          Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials.\n          Int J Neuropsychopharmacol.\n          2015;\n\t\t\t\t\t18(9):pyv047.DOI: 10.1093\/ijnp\/pyv047. PubMed PMID: 25939614; PubMed Central PMCID: PMC4576518.","DOI":"10.1093\/ijnp\/pyv047"},{"key":"2022110313260911000_i2168-9709-12-5-300-b33","doi-asserted-by":"crossref","unstructured":"Brakoulias\n              V,\n            \n            \n              Stockings\n              E.\n            \n          \n          A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.\n\t\t\t\t\tExpert Opin Pharmacother.\n\t\t\t\t\t2019;\n\t\t\t\t\t20(1):\n\t\t\t\t\t47-\n\t\t\t\t\t53.\n\t\t\t\t\tDOI: 10.1080\/14656566.2018.1540590. PubMed PMID: 30360669.","DOI":"10.1080\/14656566.2018.1540590"},{"key":"2022110313260911000_i2168-9709-12-5-300-b34","doi-asserted-by":"crossref","unstructured":"Erzegovesi\n              S,\n            \n            \n              Guglielmo\n              E,\n            \n            \n              Siliprandi\n              F,\n            \n            \n              Bellodi\n              L.\n            \n          \n          Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.\n\t\t\t\t\tEur Neuropsychopharmacol.\n\t\t\t\t\t2005;\n\t\t\t\t\t15(1):\n\t\t\t\t\t69-\n\t\t\t\t\t74.\n\t\t\t\t\tDOI: 10.1016\/j.euroneuro.2004.04.004. PubMed PMID: 15572275.","DOI":"10.1016\/j.euroneuro.2004.04.004"},{"key":"2022110313260911000_i2168-9709-12-5-300-b35","doi-asserted-by":"crossref","unstructured":"Hollander\n              E,\n            \n            \n              Rossi\n              NB,\n            \n            \n              Sood\n              E,\n            \n            \n              Pallanti\n              S.\n            \n          \n          Risperidone augmentation in treatment-resistant obsessive\u2013compulsive disorder: a double-blind, placebo-controlled study.\n\t\t\t\t\tInt J Neuropsychopharm.\n\t\t\t\t\t2003;\n\t\t\t\t\t6(4):\n\t\t\t\t\t397-\n\t\t\t\t\t401.\n\t\t\t\t\tDOI: 10.1017\/S1461145703003730. PubMed PMID: 14604454.","DOI":"10.1017\/S1461145703003730"},{"key":"2022110313260911000_i2168-9709-12-5-300-b36","doi-asserted-by":"crossref","unstructured":"Muscatello\n              MRA,\n            \n            \n              Bruno\n              A,\n            \n            \n              Pandolfo\n              G,\n            \n            \n              Mic\u00f2\n              U,\n            \n            \n              Scimeca\n              G,\n            \n            \n              Romeo\n              VM,\n            \n            et al.\n          \n          Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t2011;\n\t\t\t\t\t31(2):\n\t\t\t\t\t174-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1097\/JCP.0b013e31820e3db6. PubMed PMID: 21346614.","DOI":"10.1097\/JCP.0b013e31820e3db6"},{"key":"2022110313260911000_i2168-9709-12-5-300-b37","doi-asserted-by":"crossref","unstructured":"Bloch\n              MH,\n            \n            \n              Landeros-Weisenberger\n              A,\n            \n            \n              Kelmendi\n              B,\n            \n            \n              Coric\n              V,\n            \n            \n              Bracken\n              MB,\n            \n            \n              Leckman\n              JF.\n            \n          \n          A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.\n\t\t\t\t\tMol Psychiatry.\n\t\t\t\t\t2006;\n\t\t\t\t\t11(7):\n\t\t\t\t\t622-\n\t\t\t\t\t32.\n\t\t\t\t\tDOI: 10.1038\/sj.mp.4001823. PubMed PMID: 16585942.","DOI":"10.1038\/sj.mp.4001823"},{"key":"2022110313260911000_i2168-9709-12-5-300-b38","doi-asserted-by":"crossref","unstructured":"Marder\n              SR,\n            \n            \n              Cannon\n              TD.\n            \n          \n          Schizophrenia.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t381(18):\n\t\t\t\t\t1753-\n\t\t\t\t\t61.\n\t\t\t\t\tDOI: 10.1056\/NEJMra1808803. PubMed PMID: 31665579.","DOI":"10.1056\/NEJMra1808803"},{"key":"2022110313260911000_i2168-9709-12-5-300-b39","doi-asserted-by":"crossref","unstructured":"Maina\n              G,\n            \n            \n              Albert\n              U,\n            \n            \n              Ziero\n              S,\n            \n            \n              Bogetto\n              F.\n            \n          \n          Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?\n          Int Clin Psychopharmacol.\n\t\t\t\t\t2003;\n\t\t\t\t\t18(1):\n\t\t\t\t\t23-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1097\/00004850-200301000-00004. PubMed PMID: 12490771.","DOI":"10.1097\/00004850-200301000-00004"},{"key":"2022110313260911000_i2168-9709-12-5-300-b40","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry.\n          2004;\n\t\t\t\t\t65(2):\n\t\t\t\t\t267-\n\t\t\t\t\t72.\n\t\t\t\t\tPubMed PMID: 15003083."},{"key":"2022110313260911000_i2168-9709-12-5-300-b41","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association [Internet].\n          The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia.\n\t\t\t\t\tWashington: American Psychiatric Association; c2021 [cited 2022 May 1]. Available from: https:\/\/psychiatryonline.org\/doi\/epdf\/10.1176\/appi.books.9780890424841","DOI":"10.1176\/appi.books.9780890424841"},{"key":"2022110313260911000_i2168-9709-12-5-300-b42","doi-asserted-by":"crossref","unstructured":"Castle\n              D,\n            \n            \n              Bosanac\n              P,\n            \n            \n              Rossell\n              S.\n            \n          \n          Treating OCD: what to do when first-line therapies fail.\n\t\t\t\t\tAustralas Psychiatry.\n\t\t\t\t\t2015;\n\t\t\t\t\t23(4):\n\t\t\t\t\t350-\n\t\t\t\t\t3.\n\t\t\t\t\tDOI: 10.1177\/1039856215590027. PubMed PMID: 26104775.","DOI":"10.1177\/1039856215590027"},{"key":"2022110313260911000_i2168-9709-12-5-300-b43","doi-asserted-by":"crossref","unstructured":"Ghaleiha\n              A,\n            \n            \n              Entezari\n              N,\n            \n            \n              Modabbernia\n              A,\n            \n            \n              Najand\n              B,\n            \n            \n              Askari\n              N,\n            \n            \n              Tabrizi\n              M,\n            \n            et al.\n          \n          Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.\n\t\t\t\t\tJ Psychiatr Res.\n\t\t\t\t\t2013;\n\t\t\t\t\t47(2):\n\t\t\t\t\t175-\n\t\t\t\t\t80.\n\t\t\t\t\tDOI: 10.1016\/j.jpsychires.2012.09.015. PubMed PMID: 23063327.","DOI":"10.1016\/j.jpsychires.2012.09.015"},{"key":"2022110313260911000_i2168-9709-12-5-300-b44","doi-asserted-by":"crossref","unstructured":"Modarresi\n              A,\n            \n            \n              Sayyah\n              M,\n            \n            \n              Razooghi\n              S,\n            \n            \n              Eslami\n              K,\n            \n            \n              Javadi\n              M,\n            \n            \n              Kouti\n              L.\n            \n          \n          Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial.\n\t\t\t\t\tPharmacopsychiatry.\n\t\t\t\t\t2018;\n\t\t\t\t\t51(6):\n\t\t\t\t\t263-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1055\/s-0043-120268. PubMed PMID: 29100251.","DOI":"10.1055\/s-0043-120268"},{"key":"2022110313260911000_i2168-9709-12-5-300-b45","doi-asserted-by":"crossref","unstructured":"Sahraian\n              A,\n            \n            \n              Jahromi\n              LR,\n            \n            \n              Ghanizadeh\n              A,\n            \n            \n              Mowla\n              A.\n            \n          \n          Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t2017;\n\t\t\t\t\t37(2):\n\t\t\t\t\t246-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1097\/JCP.0000000000000651. PubMed PMID: 28099183.","DOI":"10.1097\/JCP.0000000000000651"},{"key":"2022110313260911000_i2168-9709-12-5-300-b46","doi-asserted-by":"crossref","unstructured":"Haghighi\n              M,\n            \n            \n              Jahangard\n              L,\n            \n            \n              Mohammad-Beigi\n              H,\n            \n            \n              Bajoghli\n              H,\n            \n            \n              Hafezian\n              H,\n            \n            \n              Rahimi\n              A,\n            \n            et al.\n          \n          In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).\n\t\t\t\t\tPsychopharmacol (Berl).\n\t\t\t\t\t2013;\n\t\t\t\t\t228(4):\n\t\t\t\t\t633-\n\t\t\t\t\t40.\n\t\t\t\t\tDOI: 10.1007\/s00213-013-3067-z. PubMed PMID: 23525525.","DOI":"10.1007\/s00213-013-3067-z"},{"key":"2022110313260911000_i2168-9709-12-5-300-b47","doi-asserted-by":"crossref","unstructured":"Modarresi\n              A,\n            \n            \n              Chaibakhsh\n              S,\n            \n            \n              Koulaeinejad\n              N,\n            \n            \n              Koupaei\n              SR.\n            \n          \n          A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder.\n\t\t\t\t\tPsychiatry Res.\n\t\t\t\t\t2019;\n\t\t\t\t\t282:\n\t\t\t\t\t112602.\n\t\t\t\t\tDOI: 10.1016\/j.psychres.2019.112602. PubMed PMID: 31630042.","DOI":"10.1016\/j.psychres.2019.112602"},{"key":"2022110313260911000_i2168-9709-12-5-300-b48","doi-asserted-by":"crossref","unstructured":"Andrade\n              C.\n            \n          \n          Augmentation with memantine in obsessive-compulsive disorder.\n          J Clin Psychiatry.\n          2019;\n\t\t\t\t\t80(6):19f13163.DOI: 10.4088\/JCP.19f13163. PubMed PMID: 31846244.","DOI":"10.4088\/JCP.19f13163"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/5\/300\/3139012\/i2168-9709-12-5-300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/5\/300\/3139012\/i2168-9709-12-5-300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:32Z","timestamp":1731687812000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/12\/5\/article-p300.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2022.10.300","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}